Company: ReNeuron Limited
Job title: Vice President, Regulatory Affairs & Pharmacovigilance
Shaun Stapleton is VP Regulatory Affairs and Pharmacovigilance at ReNeuron Limited, a UK-based biotech in clinical stage development of stem cell products.
He joined ReNeuron in 2015 from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, he began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.